Shattuck Labs, Inc. (STTK)
NASDAQ: STTK · Real-Time Price · USD
2.080
-0.050 (-2.35%)
Nov 28, 2025, 4:00 PM EST - Market closed
Shattuck Labs Revenue
Shattuck Labs had revenue of $1.00M in the quarter ending September 30, 2025, a decrease of -66.63%. This brings the company's revenue in the last twelve months to $1.00M, down -84.46% year-over-year. In the year 2024, Shattuck Labs had annual revenue of $5.72M with 245.26% growth.
Revenue (ttm)
$1.00M
Revenue Growth
-84.46%
P/S Ratio
119.89
Revenue / Employee
$22,727
Employees
44
Market Cap
131.62M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.72M | 4.06M | 245.26% |
| Dec 31, 2023 | 1.66M | 1.01M | 154.14% |
| Dec 31, 2022 | 652.00K | -29.37M | -97.83% |
| Dec 31, 2021 | 30.02M | 20.08M | 202.16% |
| Dec 31, 2020 | 9.93M | 47.00K | 0.48% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
STTK News
- 8 days ago - Shattuck Labs to Participate in Upcoming December Investor Conferences - GlobeNewsWire
- 22 days ago - Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 6 weeks ago - Shattuck Labs, Inc. (STTK) Presents at The United European Gastroenterology (UEG) Congress UEG Week 2025 Transcript - Seeking Alpha
- 2 months ago - Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel - GlobeNewsWire
- 3 months ago - Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors - GlobeNewsWire
- 3 months ago - Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease - GlobeNewsWire
- 3 months ago - Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 4 months ago - Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million - GlobeNewsWire